Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.

By Derek Lowe

Posts tagged with "Alzheimer’s Disease"

• Alzheimer's Disease

  Clinical Trials, Up and Very Much Down

  1 December, 2016

  Lots of news at both ends of the scale today. At the bad end would be Arrowhead Pharma, who have been exploring therapeutic RNA interference. That’s a hard row to hoe, and nothing illustrates that better than their announcement that they’re dropping three clinical programs, pretty much all the advanced research that they have, because… Read More

• Academia (vs. Industry)

  Vanderbilt Heads Into the Clinic for Alzheimer’s

  29 November, 2016

  There’s an interesting experiment underway at Vanderbilt, where a team from the university is taking a possible Alzheimer’s candidate into clinical trials on their own. Now, you could come up with several headlines for this, along the lines of “Academic researchers in way over their heads”, or “Plucky professors make e… Read More

• Alzheimer's Disease

  Eli Lilly’s Alzheimer’s Antibody Does Not Work

  23 November, 2016

  After years of work and untold amounts of money, Eli Lilly’s Alzheimer’s antibody, solanezumab, does not work. It does not help Alzheimer’s patients. No matter how many times you run the Phase III trials, or in which patient populations, they do not get better. No matter how many hopeful press articles you might have seen… Read More

• Alzheimer's Disease

  A New Way to Make GSK3 Inhibitors

  17 November, 2016

  Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I started reading the literature, I quickly felt as if I were late to the party. It’s been investigated for diabetes (and other metabolic diseases), Alzheimer’s… Read More

• Alzheimer's Disease

  The Best Beta-Secretase Inhibitor Yet in Alzheimer’s

  4 November, 2016

  Merck has published new results on their latest Alzheimer’s drug candidate, the beta-secretase inhibitor verubecestat (MK-8931). The paper in Science Translational Medicine is quite interesting, both for what it says and what it doesn’t (or can’t, yet). BACE inhibitors have had quite a time of it over the years. Coming up with a m… Read More

• Alzheimer's Disease

  The Limits of Big Data

  21 October, 2016

  I fear that mentioning the phrase “Big Data” in the first sentence of a blog post will make half the potential readers suddenly remember that they have podiatrist appointments or something. But that’s the only way to approach this article at Wired. After all, the title is “The Cure For Cancer is Data – Mountains of… Read More

• Alzheimer's Disease

  Bill Gates and His Moonshot

  7 October, 2016

  The rocket’s supposed to be moving, and it probably is, but everyone knows that you can’t see that with the naked eye. Not at first. The announcer said “Lift-off” – well, that probably happened sometime during the lunch hour, it’s easy to miss – and the first thing you look for is the exhaust starting… Read More

• Alzheimer's Disease

  Just How Worthless Are the Standard Alzheimer’s Models?

  23 September, 2016

  As mentioned yesterday, Alzheimer’s therapies have, for the most part, been a cliff over which people push bales of money. There are plenty of good reasons for this: we don’t really know what the cause of Alzheimer’s is, when you get down to it, and we’re the only animal that we know of that gets… Read More

• Alzheimer's Disease

  Does Axovant Have Any Hope in Alzheimer’s?

  22 September, 2016

  Hey, remember Axovant? That’s the company that acquired a shelved Alzheimer’s candidate from GSK (intepirdine) and promptly went public in June of 2015 at what seemed a ridiculous valuation ($15/share, raising $315 million). People certainly made money on it, but jeez, the whole business really had a nasty look to it. The company’… Read More

• Alzheimer's Disease

  TauRx Reports on Their Alzheimer’s Drug. Unfortunately.

  28 July, 2016

  It’s been a while since we heard from TauRx, the company that’s been developing an unusual Alzheimer’s therapy targeting tau protein instead of amyloid. They released interesting Phase II data some time ago, but they’ve been improving their formulation and going into a larger, longer Phase III, which is what anyone working… Read More